Entering text into the input field will update the search result below

CEL-SCI nabs European patent covering LEAPS vaccine for rheumatoid arthritis

Sep. 18, 2020 9:20 AM ETCEL-SCI Corporation (CVM) StockBy: Vandana Singh, SA News Editor1 Comment
  • The European Patent Office has issued patent to CEL-SCI (NYSE:CVM) titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.
  • We are in the process of completing pre-IND studies for CEL-4000, being developed against Rheumatoid Arthritis, and hope to start human studies with CEL-4000 next year. LEAPS is also currently being tested at the University of Georgia vaccine center against COVID-19,” said Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology.
  • LEAPS is under development as a therapeutic vaccine for rheumatoid arthritis with support of a NIAMS grant of the National Institutes of Health.
  • Shares are up 1.3% in premarket.

Recommended For You

About CVM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVM--
CEL-SCI Corporation